So far, exploiting PD-L1/PD-1 signaling as a biomarker for corresponding immune checkpoint blockade has not been conclusive in RCC patients [12, 17, 22] and the relationship between PD-L1 tumor expression and sPD-L1 in blood is unclear. This evidence concerns the gene CD274 and renal cell carcinoma.